Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunonutrition for Diabetic Foot Ulcers
NCT05281562Phase 3Terminated
- Sponsor
- Prisma Health
- Start
- Feb 2023
- Primary completion
- Mar 2023
- Modality
- Peptides, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of eicosapentaenoic acid + docosahexaenoic acid, arginine and ascorbic acid in diabetic foot ulcer (DFU) (2 arms), sponsored by Prisma Health. Primary endpoints: Effect of Supplemental Immunonutrition on Wound Healing in Patients With Diabetic Foot Ulcers as Assessed by the Pressure Ulcer Scale for Healing (PUSH) Tool 3.0 at 6 weeks and Effect of Supplemental Immunonutrition on Patient Reported Pain Scores at 6 weeks. Started Feb 2023; status: terminated.
02
Drugs
eicosapentaenoic acid + docosahexaenoic acidarginineascorbic acid
03
Conditions
diabetic foot ulcer (DFU)
Beyond the preview
Go deeper on NCT05281562.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05281562.